WO2009011336A1 - キノリン化合物 - Google Patents
キノリン化合物 Download PDFInfo
- Publication number
- WO2009011336A1 WO2009011336A1 PCT/JP2008/062704 JP2008062704W WO2009011336A1 WO 2009011336 A1 WO2009011336 A1 WO 2009011336A1 JP 2008062704 W JP2008062704 W JP 2008062704W WO 2009011336 A1 WO2009011336 A1 WO 2009011336A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- quinoline compounds
- neuromedin
- preventives
- remedies
- anxiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
式（Ｉ） で示されるニューロメジンＵ－Ｒ２受容体調節作用を有する新規キノリン化合物若しくはその医薬上許容される塩、又はこれらを有効成分として含有する医薬は、うつ若しくは不安などのストレス性疾患、疼痛又は肥満などの予防又は治療薬として有用である。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-187652 | 2007-07-18 | ||
| JP2007187652 | 2007-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009011336A1 true WO2009011336A1 (ja) | 2009-01-22 |
Family
ID=40259669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/062704 Ceased WO2009011336A1 (ja) | 2007-07-18 | 2008-07-14 | キノリン化合物 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009011336A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394287B2 (en) | 2010-11-05 | 2016-07-19 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
| US9732071B2 (en) | 2015-10-01 | 2017-08-15 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003105850A1 (en) * | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| JP2004300156A (ja) * | 2003-03-31 | 2004-10-28 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| JP2005518365A (ja) * | 2001-11-27 | 2005-06-23 | メルク エンド カムパニー インコーポレーテッド | ４−アミノキノリン化合物 |
| JP2005519876A (ja) * | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| JP2006124387A (ja) * | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
-
2008
- 2008-07-14 WO PCT/JP2008/062704 patent/WO2009011336A1/ja not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005518365A (ja) * | 2001-11-27 | 2005-06-23 | メルク エンド カムパニー インコーポレーテッド | ４−アミノキノリン化合物 |
| JP2005519876A (ja) * | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| WO2003105850A1 (en) * | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| JP2004300156A (ja) * | 2003-03-31 | 2004-10-28 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| JP2006124387A (ja) * | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394287B2 (en) | 2010-11-05 | 2016-07-19 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
| US10016418B2 (en) | 2010-11-05 | 2018-07-10 | Seaomyx, Inc. | Compounds useful as modulators of TRPM8 |
| US10953007B2 (en) | 2010-11-05 | 2021-03-23 | Firmenich Incorporated | Compounds useful as modulators of TRPM8 |
| US9732071B2 (en) | 2015-10-01 | 2017-08-15 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008051942A3 (en) | Farnesoid x receptor agonists | |
| WO2009111700A3 (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
| WO2009017822A3 (en) | Pi3 kinase modulators and methods of use | |
| WO2007076260A3 (en) | Farnesoid x receptor agonists | |
| WO2008097428A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
| WO2009016410A3 (en) | Chemical compounds 831 | |
| PT2150530E (pt) | Derivados de sulfonamida substituídos | |
| WO2009156462A3 (en) | Organic compounds | |
| WO2007135527A3 (en) | Benzimidazolyl compounds | |
| WO2009024611A3 (en) | 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use | |
| WO2009051119A1 (ja) | ピリミジルインドリン化合物 | |
| IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
| MX2007014892A (es) | Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico . | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| WO2010052144A3 (en) | Neuropeptide-2-receptor (y-2r) agonists and uses thereof | |
| WO2011045232A3 (en) | Neuropeptide-2 receptor (y-2r) agonists | |
| WO2007090661A3 (en) | Active substance combination comprising azolylcarbinol compounds | |
| WO2009013545A3 (en) | Chemical compounds | |
| WO2009105969A8 (zh) | 埃坡霉素类似物、其药物组合物、用途及其制备方法 | |
| WO2008116663A3 (en) | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | |
| WO2007044796A3 (en) | Pyridazinone compounds as calcilytics | |
| WO2008131946A3 (de) | Substituierte amid-derivate | |
| WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
| WO2007098273A3 (en) | Novel crystalline forms of armodafinil and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08791129 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08791129 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |